Global Inhalation CDMO Market Research Report 2024

Publication ID:

PB509240216

Publication Date:

September 13, 2024

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Medical Devices [2]

Pharma & Healthcare [3]

Description:

Inhalation CDMO (Contract Development and Manufacturing Organization) refers to specialized companies that provide end-to-end services in the development and manufacturing of inhalable drugs and therapies. These organizations work with pharmaceutical companies to design, develop, test, and produce inhalation products, such as metered-dose inhalers, dry powder inhalers, and nebulizers. The services offered by inhalation CDMOs typically include formulation development, analytical testing, device engineering, clinical trial manufacturing, and large-scale commercial production. By leveraging their expertise, CDMOs help bring inhalation therapies to market more efficiently and with greater compliance to regulatory standards.
The global Inhalation CDMO market was valued at US$ 2816 million in 2023 and is anticipated to reach US$ 5963 million by 2030, witnessing a CAGR of 11.2% during the forecast period 2024-2030.
Inhalation Contract Development and Manufacturing Organizations (CDMOs) are specialized service providers that assist pharmaceutical companies in the development and production of inhalation products, such as inhalers and nebulizers. The market for inhalation CDMOs is growing steadily, driven by the increasing prevalence of respiratory diseases like asthma and COPD, and the rising demand for complex inhalation therapies. The North America and Europe are the major sales regions, although significant growth is also expected in Asia-Pacific. Market opportunities lie in the development of novel drug delivery systems, biologics, and personalized medicine, while challenges include regulatory complexities and the high cost of development. Future product trends point towards the integration of digital health technologies and sustainable packaging solutions in inhalation products.
This report aims to provide a comprehensive presentation of the global market for Inhalation CDMO, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Inhalation CDMO.
The Inhalation CDMO market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Inhalation CDMO market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Inhalation CDMO companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Lonza
Vectura
Iconovo
CritiTech
Hovione
Recipharm
Aptar Pharma
Kindeva
Sanner
Particle Sciences
Experic
Enteris Biopharma
Catalent
HCmed
Ritedose
Bespak
Proveris
Bend Bioscience
Renejix
Segment by Type
Metered Dose Inhalers (MDIs)
Dry Powder Inhalers (DPIs)
Soft Mist Inhalers (SMIs)
Others
Segment by Application
Commercial
Academic Research
Others
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Inhalation CDMO company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Inhalation CDMO Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Metered Dose Inhalers (MDIs)
1.2.3 Dry Powder Inhalers (DPIs)
1.2.4 Soft Mist Inhalers (SMIs)
1.2.5 Others
1.3 Market by Application
1.3.1 Global Inhalation CDMO Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Commercial
1.3.3 Academic Research
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Inhalation CDMO Market Perspective (2019-2030)
2.2 Global Inhalation CDMO Growth Trends by Region
2.2.1 Global Inhalation CDMO Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Inhalation CDMO Historic Market Size by Region (2019-2024)
2.2.3 Inhalation CDMO Forecasted Market Size by Region (2025-2030)
2.3 Inhalation CDMO Market Dynamics
2.3.1 Inhalation CDMO Industry Trends
2.3.2 Inhalation CDMO Market Drivers
2.3.3 Inhalation CDMO Market Challenges
2.3.4 Inhalation CDMO Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Inhalation CDMO Players by Revenue
3.1.1 Global Top Inhalation CDMO Players by Revenue (2019-2024)
3.1.2 Global Inhalation CDMO Revenue Market Share by Players (2019-2024)
3.2 Global Inhalation CDMO Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Inhalation CDMO Revenue
3.4 Global Inhalation CDMO Market Concentration Ratio
3.4.1 Global Inhalation CDMO Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Inhalation CDMO Revenue in 2023
3.5 Global Key Players of Inhalation CDMO Head office and Area Served
3.6 Global Key Players of Inhalation CDMO, Product and Application
3.7 Global Key Players of Inhalation CDMO, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Inhalation CDMO Breakdown Data by Type
4.1 Global Inhalation CDMO Historic Market Size by Type (2019-2024)
4.2 Global Inhalation CDMO Forecasted Market Size by Type (2025-2030)
5 Inhalation CDMO Breakdown Data by Application
5.1 Global Inhalation CDMO Historic Market Size by Application (2019-2024)
5.2 Global Inhalation CDMO Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Inhalation CDMO Market Size (2019-2030)
6.2 North America Inhalation CDMO Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Inhalation CDMO Market Size by Country (2019-2024)
6.4 North America Inhalation CDMO Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Inhalation CDMO Market Size (2019-2030)
7.2 Europe Inhalation CDMO Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Inhalation CDMO Market Size by Country (2019-2024)
7.4 Europe Inhalation CDMO Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Inhalation CDMO Market Size (2019-2030)
8.2 Asia-Pacific Inhalation CDMO Market Growth Rate by Country: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Inhalation CDMO Market Size by Region (2019-2024)
8.4 Asia-Pacific Inhalation CDMO Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Inhalation CDMO Market Size (2019-2030)
9.2 Latin America Inhalation CDMO Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Inhalation CDMO Market Size by Country (2019-2024)
9.4 Latin America Inhalation CDMO Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Inhalation CDMO Market Size (2019-2030)
10.2 Middle East & Africa Inhalation CDMO Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Inhalation CDMO Market Size by Country (2019-2024)
10.4 Middle East & Africa Inhalation CDMO Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Lonza
11.1.1 Lonza Company Details
11.1.2 Lonza Business Overview
11.1.3 Lonza Inhalation CDMO Introduction
11.1.4 Lonza Revenue in Inhalation CDMO Business (2019-2024)
11.1.5 Lonza Recent Development
11.2 Vectura
11.2.1 Vectura Company Details
11.2.2 Vectura Business Overview
11.2.3 Vectura Inhalation CDMO Introduction
11.2.4 Vectura Revenue in Inhalation CDMO Business (2019-2024)
11.2.5 Vectura Recent Development
11.3 Iconovo
11.3.1 Iconovo Company Details
11.3.2 Iconovo Business Overview
11.3.3 Iconovo Inhalation CDMO Introduction
11.3.4 Iconovo Revenue in Inhalation CDMO Business (2019-2024)
11.3.5 Iconovo Recent Development
11.4 CritiTech
11.4.1 CritiTech Company Details
11.4.2 CritiTech Business Overview
11.4.3 CritiTech Inhalation CDMO Introduction
11.4.4 CritiTech Revenue in Inhalation CDMO Business (2019-2024)
11.4.5 CritiTech Recent Development
11.5 Hovione
11.5.1 Hovione Company Details
11.5.2 Hovione Business Overview
11.5.3 Hovione Inhalation CDMO Introduction
11.5.4 Hovione Revenue in Inhalation CDMO Business (2019-2024)
11.5.5 Hovione Recent Development
11.6 Recipharm
11.6.1 Recipharm Company Details
11.6.2 Recipharm Business Overview
11.6.3 Recipharm Inhalation CDMO Introduction
11.6.4 Recipharm Revenue in Inhalation CDMO Business (2019-2024)
11.6.5 Recipharm Recent Development
11.7 Aptar Pharma
11.7.1 Aptar Pharma Company Details
11.7.2 Aptar Pharma Business Overview
11.7.3 Aptar Pharma Inhalation CDMO Introduction
11.7.4 Aptar Pharma Revenue in Inhalation CDMO Business (2019-2024)
11.7.5 Aptar Pharma Recent Development
11.8 Kindeva
11.8.1 Kindeva Company Details
11.8.2 Kindeva Business Overview
11.8.3 Kindeva Inhalation CDMO Introduction
11.8.4 Kindeva Revenue in Inhalation CDMO Business (2019-2024)
11.8.5 Kindeva Recent Development
11.9 Sanner
11.9.1 Sanner Company Details
11.9.2 Sanner Business Overview
11.9.3 Sanner Inhalation CDMO Introduction
11.9.4 Sanner Revenue in Inhalation CDMO Business (2019-2024)
11.9.5 Sanner Recent Development
11.10 Particle Sciences
11.10.1 Particle Sciences Company Details
11.10.2 Particle Sciences Business Overview
11.10.3 Particle Sciences Inhalation CDMO Introduction
11.10.4 Particle Sciences Revenue in Inhalation CDMO Business (2019-2024)
11.10.5 Particle Sciences Recent Development
11.11 Experic
11.11.1 Experic Company Details
11.11.2 Experic Business Overview
11.11.3 Experic Inhalation CDMO Introduction
11.11.4 Experic Revenue in Inhalation CDMO Business (2019-2024)
11.11.5 Experic Recent Development
11.12 Enteris Biopharma
11.12.1 Enteris Biopharma Company Details
11.12.2 Enteris Biopharma Business Overview
11.12.3 Enteris Biopharma Inhalation CDMO Introduction
11.12.4 Enteris Biopharma Revenue in Inhalation CDMO Business (2019-2024)
11.12.5 Enteris Biopharma Recent Development
11.13 Catalent
11.13.1 Catalent Company Details
11.13.2 Catalent Business Overview
11.13.3 Catalent Inhalation CDMO Introduction
11.13.4 Catalent Revenue in Inhalation CDMO Business (2019-2024)
11.13.5 Catalent Recent Development
11.14 HCmed
11.14.1 HCmed Company Details
11.14.2 HCmed Business Overview
11.14.3 HCmed Inhalation CDMO Introduction
11.14.4 HCmed Revenue in Inhalation CDMO Business (2019-2024)
11.14.5 HCmed Recent Development
11.15 Ritedose
11.15.1 Ritedose Company Details
11.15.2 Ritedose Business Overview
11.15.3 Ritedose Inhalation CDMO Introduction
11.15.4 Ritedose Revenue in Inhalation CDMO Business (2019-2024)
11.15.5 Ritedose Recent Development
11.16 Bespak
11.16.1 Bespak Company Details
11.16.2 Bespak Business Overview
11.16.3 Bespak Inhalation CDMO Introduction
11.16.4 Bespak Revenue in Inhalation CDMO Business (2019-2024)
11.16.5 Bespak Recent Development
11.17 Proveris
11.17.1 Proveris Company Details
11.17.2 Proveris Business Overview
11.17.3 Proveris Inhalation CDMO Introduction
11.17.4 Proveris Revenue in Inhalation CDMO Business (2019-2024)
11.17.5 Proveris Recent Development
11.18 Bend Bioscience
11.18.1 Bend Bioscience Company Details
11.18.2 Bend Bioscience Business Overview
11.18.3 Bend Bioscience Inhalation CDMO Introduction
11.18.4 Bend Bioscience Revenue in Inhalation CDMO Business (2019-2024)
11.18.5 Bend Bioscience Recent Development
11.19 Renejix
11.19.1 Renejix Company Details
11.19.2 Renejix Business Overview
11.19.3 Renejix Inhalation CDMO Introduction
11.19.4 Renejix Revenue in Inhalation CDMO Business (2019-2024)
11.19.5 Renejix Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer

Companies Mentioned:

Lonza
Vectura
Iconovo
CritiTech
Hovione
Recipharm
Aptar Pharma
Kindeva
Sanner
Particle Sciences
Experic
Enteris Biopharma
Catalent
HCmed
Ritedose
Bespak
Proveris
Bend Bioscience
Renejix

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

91制片厂